Extended-release wax-matrix nicotinic acid with exercise yields better cardiovascular support, study shows
Highlights
- Comparison study: exercise alone, extended-release WMNA alone, or combination therapy
- Combination therapy better for cardiovascular support
- Effective WMNA dosage: 1,500 m/day
Summary
This clinical trial compared the effects of exercise therapy, extended-release, wax-matrix nicotinic acid (WMNA) treatment or the combination used for one year on the clinical course of coronary heart disease (CHD) in patients with moderate dyslipidemia.
For this study, researchers enrolled 93 patients with CHD. After one year, WMNA treatment alone is reported to improve physical performance, arterial pressure and frequency of angina attacks.
However, the combination of WMNA and exercise is reported to be more efficient than either monotherapy with improvements in physical performance, hemodynamics at rest and during exercise test, left ventricular systolic function, lipid profiles and clinical disease course.
These findings indicate that WMNA combined with exercise therapy is more effective than WMNA alone in improving the clinical course of coronary heart disease in patients with moderate dyslipidemia.
